Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.
Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.
复制标题
DOI：
--
复制
发表时间：
2002
影响因子：
2.4
通讯作者：
M. Sjögren;P. Davidsson;A. Wallin;A. Granérus;E. Grundström;H. Askmark;E. Vanmechelen;K. Blennow
中科院分区：
文献类型：
--
作者：
M. Sjögren;P. Davidsson;A. Wallin;A. Granérus;E. Grundström;H. Askmark;E. Vanmechelen;K. Blennow
tau蛋白和β -淀粉样蛋白42 （Abeta42）都与阿尔茨海默病（AD）有关，而tau蛋白单独与额颞叶痴呆（FTD）和肌萎缩侧索硬化症（ALS）有关。这些蛋白可以在脑脊液（CSF）中测量；与正常脑脊液水平的差异可能反映了病理生理机制。使用elisa，我们研究了AD （n = 19）、FTD （n = 14）、ALS （n = 11）和帕金森病（PD; n = 15）患者以及年龄匹配对照（n = 17）患者中总CSF-tau（这里称为tau）、磷酸化CSF-tau （phosphotau）和Abeta42的水平。与FTD （p < 0.001）、ALS （p < 0.001）、PD （p < 0.001）和对照组（p < 0.001）相比，AD患者CSF-tau和CSF-phosphotau均升高。与对照组相比，CSF-Abeta42在AD和ALS中显著降低（p < 0.001），在FTD和PD中略有降低（p < 0.01）。临床应用CSF-phosphotau蛋白可促进AD与FTD、ALS的鉴别。此外，CSF-Abeta42水平降低可能在神经退行性疾病中很常见，可能反映了β -淀粉样蛋白或轴突变性代谢的变化。
Both tau and beta-amyloid 42 (Abeta42) have been implicated in Alzheimer's disease (AD) and tau alone in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). These proteins can be measured in the cerebrospinal fluid (CSF); differences from normal CSF levels may reflect pathophysiological mechanisms. Using ELISAs, we investigated the levels of total CSF-tau (here referred to as tau), phosphorylated CSF-tau (phosphotau), and Abeta42 in patients with AD (n = 19), FTD (n = 14), ALS (n = 11) and Parkinson's disease (PD; n = 15) and in age-matched controls (n = 17). Both CSF-tau and CSF-phosphotau were increased in AD compared with FTD (p < 0.001), ALS (p < 0.001), PD (p < 0.001) and controls (p < 0.001). CSF-Abeta42 was markedly decreased in AD and ALS (both p < 0.001) and slightly decreased in FTD (p < 0.01) and PD (p < 0.05) compared with controls. Using CSF-phosphotau may improve the differentiation of AD from FTD and ALS in clinical praxis. Furthermore, decreased CSF-Abeta42 levels may be common in neurodegenerative disorders possibly reflecting changes in the metabolism of beta-amyloid or axonal degeneration.